Oth D, Mercier G, Perrin P, Joffret M L, Sureau P, Thibodeau L
Cell Immunol. 1987 Aug;108(1):220-6. doi: 10.1016/0008-8749(87)90206-1.
BALB/c mice were primed by receiving a unique intraperitoneal injection of rabies virus antigens presented as complete inactivated virus (P.V. strain) or as purified glycoproteins either in the aggregated form or in physical combination with liposomes (i.e., in the form of "immunosomes"). The splenocytes of these mice were restimulated, 6-15 days after priming, in culture with rabies virus antigens, and antigen-specific IL-2 production was measured. It was found that rabies antigens presented as immunosomes were as active as the inactivated virus, whereas equivalent amounts of purified glycoproteins were inactive. The optimal amounts of rabies immunosomes used for priming was found to be 0.5 to 0.05 micrograms per mouse.
通过向BALB/c小鼠腹腔内注射独特的狂犬病病毒抗原来进行初次免疫,这些抗原呈现为完全灭活病毒(P.V. 株),或为纯化糖蛋白,其形式为聚集态或与脂质体物理结合(即“免疫体”形式)。在初次免疫6至15天后,用狂犬病病毒抗原在培养中再次刺激这些小鼠的脾细胞,并检测抗原特异性白细胞介素-2的产生。结果发现,以免疫体形式呈现的狂犬病抗原与灭活病毒一样具有活性,而等量的纯化糖蛋白则无活性。用于初次免疫的狂犬病免疫体的最佳用量为每只小鼠0.5至0.05微克。